Allena Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALNAQ research report →
Companywww.allenapharma.com
Allena Pharmaceuticals, Inc. , a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease.
- IPO
- 2017
- Employees
- 12
- HQ
- Newton, MA, US
Price Chart
Valuation
- Market Cap
- $122
- P/E
- -0.07
- P/S
- 0.00
- P/B
- 0.13
- EV/EBITDA
- 0.92
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -160.99%
- ROIC
- -166.72%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-49,639,000 · -51.90%
- EPS
- $-0.73 · 27.72%
- Op Income
- $-47,649,000
- FCF YoY
- -60.87%
Performance & Tape
- 52W High
- $0.02
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -14.54
- Avg Volume
- 24.85K
Get TickerSpark's AI analysis on ALNAQ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ALNAQ Coverage
We haven't published any research on ALNAQ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ALNAQ Report →